載入中
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
前收盤價
US$1.69
+US$0.01 · +0.60%
盤中時間採用ET。市場資料可能有所延遲。
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
日內區間
目前US$1.69
52週區間
目前US$1.69
盤中時間採用ET。市場資料可能有所延遲。
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
日內區間
目前US$1.69
52週區間
目前US$1.69
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 72.34萬 USD | — | — | — | — |
| 毛利 | −72.34萬 USD | — | — | — | — |
| 研究與開發 | 4236.19萬 USD | 1870.17萬 USD | 581.95萬 USD | 601.18萬 USD | 293.14萬 USD |
| 銷售、一般及管理費用 | 1580.17萬 USD | 1772.57萬 USD | 785.23萬 USD | 609.46萬 USD | 491.63萬 USD |
| 營業費用 | 5744.02萬 USD | 3019.27萬 USD | 3473.52萬 USD | 1831.17萬 USD | 784.77萬 USD |
| 利息收入 | 188.39萬 USD | 326.35萬 USD | 10萬 USD | 1.9萬 USD | 3 USD |
| 利息支出 | — | 96.76萬 USD | 90.63萬 USD | 66.38萬 USD | 76.75萬 USD |
| 折舊和攤銷 | 72.34萬 USD | 29.86萬 USD | 12.43萬 USD | 11.5萬 USD | 3.41萬 USD |
| 營業利益 | −5816.36萬 USD | −3019.27萬 USD | −3473.52萬 USD | −1831.17萬 USD | −784.77萬 USD |
| 淨利 | −5592.48萬 USD | −2656.71萬 USD | −3764.48萬 USD | −1948.16萬 USD | −852.22萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$12.00
上漲空間 610.06%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
